Compare GSK plc (GSK) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Solaredge Technologies Inc — how do they compare? GSK plc trades at $52.46 (market cap $101.34B), while Solaredge Technologies Inc trades at $53.38 (market cap $3.32B). The key difference: GSK plc is far larger — about 30.5× Solaredge Technologies Inc's market cap, and GSK plc pays a 3.49% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| GSK | SEDG | |
|---|---|---|
Market Cap | $101.34B | $3.32B |
Sector | Health | Technology |
52-Week High | $61.18 | $78.51 |
52-Week Low | $36.20 | $24.42 |
Enterprise Value | $121.95B | $3.25B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
SolarEdge Technologies (SEDG) trades at $55.52, up 6.5% on the day, reflecting volatile solar sector momentum. The stock shows a bullish technical signal with moving averages supporting an uptrend, while fundamentals reveal significant challenges including a net income margin of -28.56% and negative ROE of -72.5% for 2025. Recent earnings have been mixed, with a Q1 2026 miss but prior beats, as the company navigates a difficult residential solar market. Cash flow improved to positive $138.6M in 2025 after negative periods, though revenue declined sharply from 2022-2023 peaks.
The outlook remains cautious with analyst consensus at 'Hold' (58.34%) and a price target of $35.65 below current trading. Opportunities exist in AI data center power demand and European market strength, but risks include persistent profitability challenges, high debt-to-asset ratio of 25.71%, and policy uncertainty affecting solar adoption. The stock trades near resistance at $56, with support at $55.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
